Targeted Oncology

Treating Together

Health EN ↓ 102 episodes

Targeted Oncology brings you Treating Together , a podcast series designed to bring oncologists into meaningful, peer-driven conversations by focusing on real-world challenges, clinical relevance of emerging data, and bridging the gap between research and frontline oncology care across different cancer types.

Be sure to visit the podcast's website and support the creator: www.targetedonc.com

Author

Targeted Oncology

Category

Health

Podcast website

www.targetedonc.com

Latest episode

Nov 17, 2026

Where to listen?

Podcasts in the app Replaio Radio Coming soon

Podcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts

Get it on Google Play Install for free Android 10M+ downloads · 4.7+ rating iOS soon

Episodes

S8 Ep12: Dr Ligibel on Quality-of-Life Gains From the BWEL Weight Loss Program in Breast Cancer 17.11.2026

After surgery, chemotherapy, and radiation, many patients with breast cancer want to know how to feel well, not only how to live longer. In this episode of Targeted Talks, Jennifer A. Ligibel, MD, a professor of medicine at Harvard Medical School and a senior physician in the Breast Oncology Center at Dana-Farber Cancer Institute, discusses quality-of-life results from the phase 3 BWEL trial.  BWE...

S8 Ep11: The Patients Missing From Breast Cancer Data 10.11.2026

A single label can hide a lot. In this episode of Targeted Talks, two researchers look at what broad racial and ethnic categories obscure in breast cancer research, and what it would take to see more clearly. First, Scarlett Lin Gomez, professor of epidemiology and biostatistics at the University of California, San Francisco, discusses a large study of survival among Asian American women with brea...

S8 Ep10: Beyond the Scan: Predicting Immunotherapy Response With ctDNA in NSCLC 03.11.2026

Valsamo “Elsa” Anagnostou, MD, PhD, of Johns Hopkins University School of Medicine, joins Targeted Talks to discuss a study on landmark circulating tumor DNA (ctDNA) molecular response in patients with metastatic non–small cell lung cancer (NSCLC) treated with immunotherapy. Radiographic imaging, the current gold standard, can be slow and imprecise at capturing immunotherapy response. Anagnostou e...

S8 Ep9: Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC 20.10.2026

On this episode of Targeted Talks , Lyudmila Bazhenova, MD, discusses the FDA’s expanded label approval of taletrectinib (Ibtrozi) for ROS1-positive non–small cell lung cancer (NSCLC). She explains that the approval is based on data already presented at the 2026 AACR Annual Meeting, which showed efficacy in both TKI-naive and TKI-pretreated patients with longer follow-up. In TKI-naive patients, po...

S8 Ep8: Lung Cancer in Hispanic and Latinx Patients: Risk Factors, Biomarkers, and Clinical Trial Access 13.10.2026

In this episode of Targeted Talks, recorded for Hispanic Heritage Month, Narjust Florez, MD, of Dana-Farber Cancer Institute, explains what oncologists should know about lung cancer in Hispanic and Latinx patients, one of the fastest-growing patient populations in the United States. Florez describes how risk factors in this population often extend beyond tobacco, including radon exposure, occupati...

S8 Ep7: Dr Jhaveri on the FDA Approval of Imlunestrant Plus Abemaciclib for ESR1-Mutated Breast Cancer 06.10.2026

Komal Jhaveri, MD, joins Targeted Talks to discuss the FDA approval of imlunestrant (Inluriyo) in combination with abemaciclib (Verzenio) for patients with ESR1 -mutated, estrogen receptor–positive, HER2-negative metastatic breast cancer. She explains the unmet need, noting that existing endocrine monotherapies leave many patients without a durable benefit. She then reviews the design of the phase...

S8 Ep6: Dr Herzberg on the Expanding Toolkit in KRAS-Mutant Non–Small Cell Lung Cancer 29.09.2026

In this episode of Targeted Talks, Benjamin Herzberg, MD, discusses the evolving treatment landscape for KRAS -mutant non–small cell lung cancer (NSCLC). He explains why KRAS matters to all oncologists, since these mutations drive roughly 30% of NSCLC cases, and reviews why chemoimmunotherapy remains the first-line standard of care for now. He also covers how central nervous system metastases affe...

S8 Ep5: ASTRO 2026 Preview: Dr Raj Singh on De-Escalation, Brain Metastases, and What's Next in Radiation Oncology 24.09.2026

Ahead of the 2026 ASTRO Annual Meeting, Dr Raj Singh of Baptist Health joins the podcast to break down the studies he's watching most closely. The conversation opens with a pooled analysis of 3 phase 2 trials using FMISO PET imaging to identify hypoxic tumor regions and select patients with HPV-positive head and neck cancer who may safely de-escalate radiation dose, and Singh discusses what it wou...

S8 Ep4: Bringing CAR T and Bispecifics to the Community 22.09.2026

Andrew Dalovisio, MD, a hematologist/oncologist at Mary Bird Perkins Cancer Center in Baton Rouge, Louisiana, discusses how his community cancer center built a CAR T and bispecific antibody program from the ground up. He walks through the toxicities associated with these T-cell–engaging therapies, including cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome...

S8 Ep3: Rethinking HER2: A Pan-Cancer Look at IHC, ERBB2, and Tumor-Agnostic Testing 15.09.2026

HER2 has long been synonymous with breast cancer, but a growing body of evidence shows it's expressed, at some level, across nearly every solid tumor type. In this episode of Targeted Talks, host Sabrina Serani sits down with Dr Aditya Shreenivas (City of Hope National Medical Center) and Dr Razelle Kurzrock (Medical College of Wisconsin Cancer Center) to unpack their new real-world analysis, publ...

S8 Ep2: Radiation Oncology's Financial Squeeze with Dr Ryan Funk 08.09.2026

In this episode of Targeted Talks, Sabrina Serani speaks with Dr Ryan Funk, chief radiation oncology officer at The US Oncology Network and a radiation oncologist with Minnesota Oncology, about the financial pressures reshaping radiation oncology in 2026. While CMS's overhaul of treatment delivery codes into complexity-based tiers has drawn attention, Dr. Funk argues that commercial payer contract...

S8 Ep1: Gynecologic Cancer Trends, Testing, and Treatment Advances Explained 01.09.2026

Gynecologic cancer incidence is moving in 3 different directions at once, and clinicians outside gynecologic oncology are often the first to see the warning signs. Ovarian cancer incidence is falling as genetic testing and risk-reducing surgery catch more high-risk women before diagnosis, even as its prevalence climbs because patients are living longer on treatment. Cervical cancer incidence conti...

S7 Ep19: AI in Oncology: Managing Information Overload for Trainees and Patients 15.07.2026

In part 2 of this conversation, oncologists discuss how they help both patients and trainees navigate an overwhelming volume of medical information. The speakers describe encouraging patients to consult reliable resources like NCCN's patient site rather than turning solely to AI chatbots, while also acknowledging patients will inevitably seek outside information and clarification from family. For...

S7 Ep18: Drowning in Data: How Oncologists Are Coping with Information Overload in the AI Era 01.07.2026

In this episode of Treating Together, host Dr Pallav Mehta sits down with Dr Kurt Demel and Dr Yan Ji, 2 community-based medical oncologists practicing in the Twin Cities, to tackle a problem every oncologist feels but few have named clearly: information overload. The conversation opens with a deceptively simple question: When does learning become overload? The group traces the line from the genui...

S7 Ep17: Navigating the 505(b)(2) Pathway: Operational, Clinical, and Economic Strategies for Oncology Practices 17.06.2026

In this episode, managing editor Sabrina Serani sits down with 3 experts at the intersection of oncology pharmacy, health informatics, and drug distribution to unpack the 505(b)(2) regulatory pathway and what it means for cancer centers navigating today's complex drug landscape. Guests: Jessica White, PharmD, Vice President, Specialty Programs & Portfolio Management at McKesson Derek Burns​, P...

S7 Ep16: ASCO 2026 Preview: Late-Breaking Abstracts Poised to Reshape the Treatment Landscape 20.05.2026

Ahead of the 2026 ASCO Annual Meeting, Sabrina Serani, managing editor of Targeted Oncology , previews the late-breaking abstracts most likely to influence clinical practice across breast, colorectal, prostate, and lung cancer, as well as in metastatic uveal melanoma, a disease that has gone without an effective systemic therapy for decades. From VIKTORIA-1 in PIK3CA- mutant metastatic breast canc...

S7 Ep15: Pediatric Blood Cancers: Building Better Outcomes Through Bold Science 06.05.2026

In this episode of the Treating Together podcast, host Pallav Mehta, MD, medical oncologist at MD Anderson Cancer Center at Cooper University Health Care and medical director of Reimagine Care, speaks with E. Anders (Andy) Kolb, MD, president and chief executive officer of Blood Cancer United (formerly The Leukemia & Lymphoma Society; LLS). Together, they unpack the major forces shaping change...

S7 Ep14: Choosing Wisely in CLL: A Deep Dive Into Frontline Treatment 15.04.2026

In this episode of Treating Together, host Marc Braunstein, MD, PhD, associate professor of medicine at the NYU Perlmutter Cancer Center, sits down with Adam Kittai, MD, associate professor and director of the CLL and Lymphoma programs at NYU Perlmutter Cancer Center, for a deep dive into the rapidly evolving frontline treatment landscape in chronic lymphocytic leukemia (CLL). As chemotherapy cont...

S7 Ep13: Leveraging AI, Social Media, and Virtual Care in the Information Age 01.04.2026

In this episode of Targeted Oncology’s Treating Together podcast, Dr Pallav Mehta sits down with Dr Sanjay Juneja, aka The Onc Doc, a medical oncologist known for his social media presence and his work in medical informatics. The duo explores how the landscape of cancer care is shifting from a "paucity of information" to a challenge of "information overload," and how technology can bridge the gap...

S7 Ep12: Beyond Monotherapy: Mechanisms and Combination Strategies in NPM1-Mutant Acute Myeloid Leukemia 27.03.2026
S7 Ep11: Treating Together: Navigating Treatment Decisions in Relapsed NPM1-Mutant AML: Practical Insights for Clinical Care 27.03.2026

Dr Gabriel Mannis from Stanford University and Dr Gail Roboz from Weill Cornell Medicine discussed the evolving treatment landscape for relapsed/refractory NPM1-mutant acute myeloid leukemia (AML). The conversation highlighted the dramatic transformation of relapsed/refractory AML management from a space where "drugs went to die" to one with multiple targeted therapeutic options. Dr Roboz emphasiz...

S7 Ep10: Beyond the Hospital Walls: Expanding Access to Complex Cancer Therapies 25.03.2026

In this episode of the Treating Together podcast, host Dr Pallav Mehta, medical oncologist at MD Anderson Cancer Center at Cooper, assistant professor of medicine at Cooper Medical School, and medical director of Reimagine Care, sits down with Jorge Garcia, PharmD, founder of Patagonia Healthcare, for an in-depth conversation about the rapidly evolving landscape of advanced cancer therapies, from...

S7 Ep9: Test First, Treat Second: ASCO's Updated Approach to Driver Mutation–Negative NSCLC 11.03.2026

In this minisode, we break down the latest update to ASCO's living guideline for stage IV non–small cell lung cancer (NSCLC) without driver mutations — and what it means for clinicians on the front lines of care. We're drawing on a conversation with Dr. Joshua Reuss , thoracic medical oncologist at Georgetown University and co-chair of ASCO's Living Guidance Committee, who helped explain the key c...

S7 Ep8: Precision Hope: The New Frontier of AI-Driven Oncology 04.03.2026

Host Pallav Mehta, MD, and guest Doug Flora, MD discuss the use of artificial intelligence (AI) in oncology. As the author of Rebooting Cancer Care, Flora argues that AI is the essential "reboot" needed for a system currently "groaning under its own weight" due to physician burnout and an unmanageable explosion of medical data.

S7 Ep7: Community Oncology at a Crossroads: Navigating Policy, Progress, and Practice 18.02.2026

In this episode of Treating Together , host Pallav Mehta, MD, medical oncologist and director of Integrative Oncology at Cooper University Health Care and medical director of Reimagine Care, is joined by Debra Patt, MD, PhD, MBA, oncologist and executive vice president at Texas Oncology. Patt also serves as the president of the Community Oncology Alliance (COA). Their discussion focuses on the rap...

Listen to the Treating Together podcast in Replaio

Radio and podcasts in one app - free, with no sign-up. Install today and do not miss the launch

Get it on Google Play

Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.